ATOSSA THERAPEUTICS INC
ATOSNASDAQTrading Snapshot
- Day Range
- $2.35 โ $2.40
- 52-Week Range
- $1.70 โ $19.35
- Volume
- $1.89B
- Avg Volume
- $1.54B
- Shares Outstanding
- 10.0M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $159,731
- Last Q Revenue
- $41,319
- P/E Ratio
- โ
- P/S Ratio
- 147.4x
- EPS (TTM)
- $-4.37
- Dividend Yield
- โ
Why Investors Own ATOS
- โHigh-growth profile โ revenue up +8.9% YoY with expanding US Equity exposure.
- โHealthy economics โ 38% gross margin and 20% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ATOSSA THERAPEUTICS INC
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share
Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026
Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer Research
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-ฮฒ/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/